Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05674513 · ClinicalTrials.gov registry record · Phase 4
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
A Phase 4 study of Contraceptive Usage, sponsored by Oregon Health and Science University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 140
- Enrollment target
- 1
- Study location
NCT05674513: Recruiting Phase 4 study of Contraceptive Usage, sponsored by Oregon Health and Science University.
NCT05674513 is a Phase 4 study of Contraceptive Usage that is actively recruiting participants, run by Oregon Health and Science University. The registered enrollment target is 140 participants, below the 615-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05674513, a Phase 4 study of Contraceptive Usage, is actively recruiting participants, sponsored by Oregon Health and Science University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 140 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
Primary Outcome
Follicular rupture (yes/no) by ultrasound. Defined as the disappearance of or \>50% reduction in size of the leading follicle
Conditions Studied
Interventions
- DRUG Ulipristal acetate
Study Locations (1)
Oregon
- OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2027-12-31 |
| Phase | Phase 4 |
What NCT05674513 shows while recruiting
NCT05674513 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 615-participant average among 11 other Contraceptive Usage trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Contraceptive Usage appearing as the primary indexed condition, and to 1 intervention - of which Ulipristal acetate is the first listed.
NCT05674513 reports a single indexed study location in Oregon.
Frequently Asked Questions
What is clinical trial NCT05674513 about?
NCT05674513 is a clinical study titled "Disparities in Emergency Contraceptive Metabolism Dictate Efficacy". The purpose of this study is to learn more about why some people are at greater risk for oral emergency contraceptive failure while others are not. The investigators want to learn if genetic differences impact the risk of emergency contraception failure.
What is the current status of trial NCT05674513?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 140 participants. The study started on 2023-01-09. Estimated completion is 2027-12-31.
What conditions does trial NCT05674513 study?
This clinical trial studies the following conditions: Contraceptive Usage.
What interventions are being tested in trial NCT05674513?
The interventions under investigation include: Ulipristal acetate (DRUG).
Who is sponsoring clinical trial NCT05674513?
This trial is sponsored by Oregon Health and Science University, which has 546 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05674513 being conducted?
This trial has 1 study location across Oregon. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Contraceptive Usage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05674513's enrollment target sits among peer trials
140 7th of 11 higher than 5 of 11 other Contraceptive Usage trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Contraceptive Usage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
RCT Evaluating Standardized Counseling on Early Discontinuation for Irregular Bleeding in Nexplanon Users
ACTIVE NOT RECRUITING · Phase 4
-
Assess Performance Attributes and Acceptability of Non-medicated Intravaginal Rings Among Sexually Active Women in Atlanta, GA
RECRUITING · Early Phase 1
-
Effectiveness Testing of a Videogame Intervention (No Baby No) to Decrease Contraception Non-use Among Adolescents.
RECRUITING · NA
-
The Over The Counter Pill National Study
ACTIVE NOT RECRUITING
-
Sexual Health Empowerment for Women's Health
ACTIVE NOT RECRUITING · NA
-
Improving Effective Contraceptive Use Among Opioid-maintained Women: Stage II
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI